Dr. Mark Ball on the future of kidney cancer treatment – NCI Center for Cancer Research

NCI Center for Cancer Research shared on LinkedIn:

“CANCER CURRENTS: In a large clinical trial, treatment with pembrolizumab (Keytruda) after surgery helped people with kidney cancer live longer than those who got a placebo and standard monitoring. The findings mark the first time an adjuvant treatment for kidney cancer has improved survival.

Dr. Mark Ball, an attending surgeon and associate research physician in our Urologic Oncology Branch, weighed in on these findings and what they may mean for the future of kidney cancer treatment.

Read more.”

Source: NCI Center for Cancer Research/LinkedIn